Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function

• Published in: Journal of clinical oncology Vol. 24; no. 28; pp. 4558 - 4564
• Main Authors: SIEGEL-LAKHAI, Wandena S, CRUL, Mirjam, DE PORRE, Peter, ZHANG, Steven, CHANG, Ilsung, BOOT, Henk, BEIJNEN, Jos H, SCHELLENS, Jan H. M
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.10.2006; Lippincott Williams & Wilkins
• Subjects: Adult; Aged; Area Under Curve; Biological and medical sciences; Farnesyltranstransferase - antagonists & inhibitors; Female; Humans; Liver - drug effects; Liver - enzymology; Liver - pathology; Male; Medical sciences; Middle Aged; Models, Statistical; Neoplasms - drug therapy; Neutrophils - drug effects; Quinolones - administration & dosage; Quinolones - pharmacology; Time Factors; Tumors; Antineoplastic agent; Human; Liver function; Cancerology; Enzyme; Transferases; Enzyme inhibitor; Tipifarnib; Malignant tumor; Farnesyl-diphosphate farnesyltransferase; Cancer

This study explored the feasibility of treating patients with impaired hepatic function with tipifarnib. The safety profile, pharmacokinetics, and relationship between the pharmacokinetics and toxicities were evaluated. Patients with mildly or moderately impaired hepatic function (Child-Pugh classif...